NASDAQ: GALT
Galectin Therapeutics Inc Stock Ownership - Who owns Galectin Therapeutics?

Insider buying vs selling

Have Galectin Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Richard E. UihleinDirector2026-07-312,550,932$4.05
$10.33MBuy
Richard E. UihleinDirector2026-07-3131,825,235$3.00
$95.48MBuy
Khurram JamilChief2026-07-1416,250$5.13
$83.28kSell
Khurram JamilChief2026-07-1416,250$3.04
$49.40kBuy
Khurram JamilChief Medical Officer2026-06-2947,467$5.04
$239.23kSell
Khurram JamilChief Medical Officer2026-06-2947,467$2.50
$118.67kBuy
Harold H. ShlevinDirector2026-06-2922,268$1.23
$27.39kBuy
Harold H. ShlevinDirector2026-06-2922,268$5.04
$112.23kSell
Khurram JamilChief Medical Officer2026-06-262,037$5.00
$10.19kSell
Khurram JamilChief Medical Officer2026-06-262,533$2.50
$6.33kBuy

1 of 8

GALT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GALT insiders and whales buy or sell their stock.

GALT Shareholders

What type of owners hold Galectin Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Richard E. Uihlein54.64%55,101,939$160.35MInsider
10x Fund LP22.08%22,271,880$64.81MInsider
James C. Czirr20.84%21,015,907$61.16MInsider
Rod D. Martin11.96%12,057,197$35.09MInsider
David Platt8.35%8,418,743$24.50MInsider
Joel Lewis0.83%836,592$2.43MInsider
Kevin D. Freeman0.23%229,332$667.36kInsider
Arthur Greenberg0.11%109,445$318.48kInsider
Peter G. Traber0.11%107,333$312.34kInsider
Steven Prelack0.11%107,189$311.92kInsider

1 of 3

GALT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GALT0.01%99.99%Net Buying
GLSI0.01%89.01%Net Buying
BNTC0.09%8.10%Net Buying
XFOR0.11%7.72%Net SellingNet Selling
RLMD0.10%3.69%Net BuyingNet Buying

Galectin Therapeutics Stock Ownership FAQ

Who owns Galectin Therapeutics?

Galectin Therapeutics (NASDAQ: GALT) is owned by 0.02% institutional shareholders, 119.69% Galectin Therapeutics insiders, and 0.00% retail investors. Richard E. Uihlein is the largest individual Galectin Therapeutics shareholder, owning 55.10M shares representing 54.62% of the company. Richard E. Uihlein's Galectin Therapeutics shares are currently valued at $164.20M.

If you're new to stock investing, here's how to buy Galectin Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.